Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Judd Klingerman's selected project will take him to Madrid, Spain, for six weeks this summer.

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...

AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new drug last month and ...